Cargando…
PD-L1 testing by immunohistochemistry in immuno-oncology
Immunotherapy, based on immune checkpoint inhibitors (ICIs) targeting the programmed cell death ligand 1 (PD-L1) and/or programmed death receptor 1 (PD-1), has substantially improved the outcomes of patients with various cancers. However, only ~30% of patients benefit from ICIs. Tumor PD-L1 expressi...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901897/ https://www.ncbi.nlm.nih.gov/pubmed/35964287 http://dx.doi.org/10.17305/bjbms.2022.7953 |